Skip to content

Neuropace, Inc. NPCE Share Buybacks

Share Buybacks at other companies

Medtronic logo
MedtronicMDT
$435M+58.8%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$0-100%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$14.57M+130%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$54M-64.0%
ITG
Integer HoldingsITGR
$50M
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$3.36M

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s share buybacks?
Neuropace, Inc. (NPCE) reported share buybacks of $0 in Q1 2026.
How has Neuropace, Inc.'s share buybacks changed year-over-year?
Neuropace, Inc.'s share buybacks decreased by 100.0% year-over-year, from $49.55M to $0.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.